Please login to the form below

Not currently logged in
Email:
Password:

Watson to buy products from Teva's Barr acquisition

Speciality pharmaceutical company Watson has signed an agreement to purchase 17 generic pharmaceutical products from Teva

Speciality pharmaceutical company Watson has signed an agreement to purchase 17 generic pharmaceutical products, 15 of which have FDA-approval, which are being divested as part of Teva's acquisition of Barr Pharmaceuticals.

The product acquisition is subject to Teva's merger with Barr and will see Watson make an upfront payment to Teva of $36m with additional milestone payments throughout the product development stages.

"These products represent a sound complement to our extensive generics portfolio," said Paul Bisaro, president and CEO of Watson. He added: "We anticipate these new generics will have immediate value that we will begin to realise in early 2009."

Teva will supply the products to Watson under a manufacturing and supply agreement until manufacturing is transferred to Watson or a third party.

25th November 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...

Infographics